Clinical trials: Psychiatric Illness
Mild Cognitive Impairment, Dementia
Validation of acceXible's Automated Speech Analysis Method for the Early Detection and Monitoring of Patients With Mild Impairment or Dementia in Primary Care
Dementia, especially dementia caused by Alzheimer's disease, is considered one of the most severe health problems of our time. It is currently known that the disease begins many years before clinical symptoms appear.
- Trial name
- NCT05380297
- Testing
- Speech analysis
- Where
- Spain
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Accexible
Alzheimer's Disease
AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
The study will evaluate the safety \& efficacy of AC-1204, a ketogenic compound, administered orally on a daily basis for 6 months.
- Trial name
- ALERT (NCT01211782)
- Testing
- caprylic triglyceride, long-chain triglyceride
- Where
- United States
- Sponsor
- Cerecin
ADHD
The Efficacy and Safety of PRC-063 in Adult ADHD Patients
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adults with ADHD
- Trial name
- NCT02139124
- Testing
- PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg
- Where
- 38 sites in United States, Canada
- Volunteers
- 375 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Major Depressive Disorder
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
Primary Objective: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.
- Trial name
- NCT00073762
- Testing
- DVS-233 SR
- Volunteers
- 375 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder
Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese Subjects
The study was designed to describe the relationship between dose and pharmacokinetic parameters of paroxetine over the range of proposed dosage strengths of the paroxetine CR tablet (12.5 to 37.5 mg) as well as safety profile
- Trial name
- NCT00406003
- Testing
- Paroxetine controlled release tablet
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Attention Deficit Disorder With Hyperactivity
Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)
The survey is designed to identify non-compliant Attention Deficit Hyperactivity Disorder (ADHD) patients who are currently on Immediate- Released Methylphenidate (IR-MPH) and observe any change in compliance after treating with…
- Trial name
- NCT00460720
- Testing
- Observational treatment compliance survey
- Volunteers
- 591 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Alzheimer's Disease
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Re-read of brain amyloid scans acquired in previous AV-45 clinical studies by readers trained using updated reading methodology.
- Trial name
- NCT01565382
- Testing
- florbetapir F 18
- Volunteers
- 40 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).
- Trial name
- MCI (NCT02016560)
- Testing
- florbetapir F 18, Flortaucipir F18, Brain PET Scan
- Where
- 27 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Severe Personality Disorder
The (Cost-)Effectiveness of Generalist Versus Specialist Treatment for Severe Personality Disorders'
The goal of this clinical trial is to investigate if generalist treatment (GIT-PD) is non-inferior in improving level op personality functioning compared to specialist treatment (MBT/ST) in patients with severe personality…
- Trial name
- P-DAET (NCT06789380)
- Testing
- Schema therapy, Mentalization-based treatment, Guideline-informed treatment for personality disorders
- Where
- 5 sites in Netherlands
- Volunteers
- 358 people
- Sponsor
- Arkin
Alzheimer's Dementia
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia
- Trial name
- NCT06534723
- Testing
- Wujia Yizhi granules
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
Alzheimer Disease
Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease
The aim of this study is to evaluate the safety, feasibility, tolerability and efficacy of a new buccal film of montelukast in patients with mild to moderate Alzheimer's disease.
- Trial name
- BUENA (NCT03402503)
- Testing
- Montelukast buccal film
- Where
- 12 sites in Canada
- Volunteers
- 52 people
- Sponsor
- IntelGenx Corp.
Alzheimer Disease, Dementia
Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias
This study will evaluate Jigsawdio, a personalized multisensory jigsaw puzzle platform, for adults aged 60 years and older with mild cognitive impairment or mild dementia.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment
- Trial name
- NCT07839286
- Testing
- Jigsawdio Multisensory Puzzle Platform, Standard Jigsaw Puzzle Activity
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Callahan-Young LLC DBA Jigsawdio
Tourette's Disorder (TD)
Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder
To evaluate the long-term efficacy of oral aripiprazole in pediatric participants for the treatment of Tourette's Disorder (TD).
- Trial name
- NCT03661983
- Testing
- Aripiprazole
- Where
- 42 sites in United States, Canada and 1 more
- Volunteers
- 36 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Bioequivalence Fasting Study in Patients
To compare and evaluate the oral bioavailability of Asenapine Sublingual Tablets, 10 mg manufactured by AMNEAL PHARMACEUTICALS, USA with SAPHRIS® (asenapine) sublingual tablets, 10 mg.
- Trial name
- NCT02072954
- Testing
- Asenapine Sublingual Tablets 10 mg
- Where
- 2 sites in India
- Volunteers
- 48 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Alzheimer's Disease
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.
- Trial name
- NCT01097096
- Testing
- CAD106, Alum, MF59
- Where
- 31 sites in United States, Belgium and 8 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
The purpose of this study is to: Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after…
- Trial name
- NCT07214727
- Testing
- ALN-5288
- Where
- 13 sites in Canada, Netherlands and 2 more
- Volunteers
- 50 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimer Disease
Study of ASN51 in Adults With Early Alzheimer's Disease
The main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (PK), and preliminary effects on measures of clinical efficacy of…
- Trial name
- NCT06677203
- Testing
- ASN51
- Where
- 7 sites in United States
- Volunteers
- 123 people
- Sponsor
- Asceneuron S.A.
Major Depressive Disorder (MDD)
A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder
The purpose of this study is to assess nausea severity in response to four different drug dosing strategies of Duloxetine (30 mg with food, 60 mg with food, 30 mg without food, and 60 mg without food) in Korean patients with…
- Trial name
- NCT00960986
- Testing
- Duloxetine hydrochloride
- Where
- 7 sites in South Korea
- Volunteers
- 249 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.
Study of the Safety, tolerability and pharmacokinetics with multiple doses of donepezil patch in healthy male subjects
- Trial name
- NCT02178124
- Testing
- Donepezil
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Icure Pharmaceutical Inc.
Alzheimer's Disease
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers.
- Trial name
- NCT00329082
- Testing
- LY2062430
- Where
- 6 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.